TB-500 dangers: separating real concerns from internet panic
TB-500 is generally well-tolerated, but a few real concerns deserve attention. Here's a calm, evidence-based review.
by Editorial team
What's actually been reported
TB-500 has a benign acute side effect profile in observational use. Most users report nothing beyond occasional mild lethargy in the first week and standard injection-site reactions.
Some users report a temporary increase in fatigue during the loading phase (higher doses for the first few weeks), which typically resolves on maintenance dosing.
The cancer angiogenesis question
Like BPC-157, TB-500 promotes cell migration and angiogenesis. The theoretical concern about active cancer is real and worth taking seriously. Most informed clinicians avoid use in patients with active or recently treated cancers.
There's no clear evidence that TB-500 causes cancer in healthy users — but the long-term data simply doesn't exist either way.
What's overblown online
Claims that TB-500 'damages the heart' or 'causes liver failure' come from animal studies at doses far above human use, or from confusion with other compounds. The honest picture: limited long-term data, but no consistent serious adverse event signal in observational human use.